Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal ...

Johnson & Johnson MedTech reported positive data for the Abiomed Impella ECP transvalvular axial flow pump system.

A ventricular assist device (VAD) helps pump blood from your heart to the rest of your body. It’s used when your heart is not able to pump enough blood on its own. The device consists of a pump, tubes ...

Hence, this device underwent several modifications (HeartMate XVE). Despite these changes, the post-REMATCH study, which included 309 patients with a HeartMate XVE, did not show substantial ...

A ventricular assist device (VAD) is a treatment option for people with stage D heart failure. It is a mechanical pump that ...

What are Ventricular Assist Devices? Ventricular Assist Devices (VADs) are mechanical heart pumps. 1 They use electrical and mechanical technology to support cardiac functioning by helping blood ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Appropriate selection of a device is of critical importance to achieve the best outcome. The following needs to be taken into account: etiology of heart failure and anticipated duration of support ...

three subanalyses of data from the company’s DanGer Shock trial explored how Impella pumps help the body recover from a severe heart attack and cardiogenic shock, as well as the devices ...

Johnson & Johnson said Monday that a pivotal trial for the Impella ECP heart pump met its primary endpoint, positioning the company to seek Food and Drug Administration approval for the device.

Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and the global leader in heart recovery. The pivotal investigational device ... support and left ventricular (LV ...

DANVERS, Mass., Oct. 28, 2024 /PRNewswire/ -- Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported ...